AbCellera reports Q1 net loss $43.2M; positive Phase 1 data for ABCL635 supports monthly dosing

AbCellera Biologics Inc.

2026-Q1 EPS reported -$0.14 revenue$8,315,000

Net loss of $43.2M ($0.14 loss per share) vs $45.6M loss in Q1 2025; revenue $8.3M up from $4.2M.
Total available liquidity ~$655M ($531M cash + $124M non-dilutive government funding).
ABCL635 Phase 1: favorable tolerability, no liver toxicity; half-life ~24 days supports monthly subcutaneous dosing.
ABCL635 showed sustained dose-dependent suppression of testosterone, a validated NK3R biomarker.
Partner-led programs with downstreams: 40 (down from 44); 14 molecules in clinic unchanged.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.